Your browser doesn't support javascript.
Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: A multi-center retrospective study in Hubei, China.
Wei, Jielin; Wu, Mengjiao; Liu, Jing; Wang, Xu; Xia, Pengfei; Peng, Ling; Huang, Yu; Liu, Cuiwei; Xia, Zihan; Chen, Chuang; Zhao, Yanxia.
  • Wei J; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. Electronic address: weijielin@hust.edu.cn.
  • Wu M; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. Electronic address: wumengjiaos@163.com.
  • Liu J; Department of Medical Oncology, Huanggang Central Hospital, Huanggang, Hubei, 438000, China. Electronic address: liujingzhongliu@163.com.
  • Wang X; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. Electronic address: tjmuwangxu@163.com.
  • Xia P; Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. Ele
  • Peng L; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. Electronic address: 15527306476@163.com.
  • Huang Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. Electronic address: riguangbed@126.com.
  • Liu C; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. Electronic address: cuiweiliu19870620@163.com.
  • Xia Z; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. Electronic address: xiazihan0623@gmail.com.
  • Chen C; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China. Electronic address: chenc2469@163.com.
  • Zhao Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. Electronic address: sophia7781@126.com.
Breast ; 59: 102-109, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1283953
ABSTRACT

BACKGROUND:

The COVID-19 pandemic is a significant worldwide health crisis. Breast cancer patients with COVID-19 are fragile and require particular clinical care. This study aimed to identify the clinical characteristics of breast cancer patients with COVID-19 and the risks associated with anti-cancer treatment.

METHODS:

The medical records of breast cancer patients with laboratory-confirmed COVID-19 were collected among 9559 COVID-19 patients from seven designated hospitals from 13th January to 18th March 2020 in Hubei, China. Univariate and multivariate analyses were performed to assess risk factors for COVID-19 severity.

RESULTS:

Of the 45 breast cancer patients with COVID-19, 33 (73.3%) developed non-severe COVID-19, while 12 (26.7%) developed severe COVID-19, of which 3 (6.7%) patients died. The median age was 62 years, and 3 (6.7%) patients had stage IV breast cancer. Univariate analysis showed that age over 75 and the Eastern Cooperative Oncology Group (ECOG) score were associated with COVID-19 disease severity (P < 0.05). Multivariate analysis showed that patients who received chemotherapy within 7 days had a significantly higher risk for severe COVID-19 (logistic regression model RR = 13.886, 95% CI 1.014-190.243, P = 0.049; Cox proportional hazards model HR = 13.909, 95% CI 1.086-178.150, P = 0.043), with more pronounced neutropenia and higher LDH, CRP and procalcitonin levels than other patients (P < 0.05).

CONCLUSIONS:

In our breast cancer cohort, the severity of COVID-19 could be associated with baseline factors such as age over 75 and ECOG scores. Chemotherapy within 7 days before symptom onset could be a risk factor for severe COVID-19, reflected by neutropenia and elevated LDH, CRP and procalcitonin levels.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Breast Neoplasms / SARS-CoV-2 / COVID-19 / Neutropenia / Antineoplastic Agents Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Middle aged Country/Region as subject: Asia Language: English Journal: Breast Journal subject: Endocrinology / Neoplasms Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Breast Neoplasms / SARS-CoV-2 / COVID-19 / Neutropenia / Antineoplastic Agents Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Middle aged Country/Region as subject: Asia Language: English Journal: Breast Journal subject: Endocrinology / Neoplasms Year: 2021 Document Type: Article